Status: Recruiting
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Manish PatelUpdated: Dec 31, 2025Locations: 7
Eligibility criteria
Written informed consent and HIPAA authorization for release of personal health... [+19]
Women of childbearing age with a positive serum pregnancy test within 72 hours p... [+18]